Evidence map›Paper›PMID 40820046›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

The impact of swithching faricimab in the treatment of neovascular age-related macular degeneration: a real-world analysis.

Giacomo Boscia, Devinder Chauhan, Giulia Corradetti, Charles P O'Neill, Gihan Samarasinghe, Sophiana M Lindenberg, Anna Urrea, Stephanie Mauger, Giang Do, Muneeswar Gupta and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giacomo BosciaDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
Devinder ChauhanMacuject Pty Ltd, Melbourne, VIC, Australia.
Giulia CorradettiDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
Charles P O'NeillAustralian National University, Canberra, ACT, Australia.
Gihan SamarasingheMacuject Pty Ltd, Melbourne, VIC, Australia.
Sophiana M LindenbergDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
Anna UrreaDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
Stephanie MaugerMacuject Pty Ltd, Melbourne, VIC, Australia.
Giang DoDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
Muneeswar GuptaDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA.
SriniVas R SaddaDoheny Eye Institute, 150 N Orange Grove Blvd, Pasadena, CA, USA. SSadda@doheny.org.ORCID 0000-0002-4939-3306

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo report a real-world analysis of switching to faricimab in the setting of neovascular age-related macular degeneration (nAMD), with regards to fluid volumes on optical coherence tomography (OCT), treatment interval, and best corrected visual acuity (BCVA).

methodsWe retrospectively collected the OCT scans of all eyes that were being treated with anti-vascular endothelial growth factor (VEGF) therapy and were switched to faricimab in clinical the practices of eight retina specialists at five clinics in three Australian states (CORRNet Study Group; Clinical Ophthalmologists’ Real-world Research Network). Only those that remained on faricimab are the subject of this report. All OCT scans were analyzed for both the presence and volume of intraretinal fluid (IRF) and subretinal fluid (SRF) using machine learning (ML) algorithms (Macuject Pty Ltd, Melbourne, Australia). Mean interval time between injections and BCVA were recorded at the time of switch and after the switch to faricimab.

resultsOf the 3082 eyes of 2200 patients treated with intravitreal anti-VEGF injections for nAMD, 473 eyes (84.0% of those switched to faricimab) remained on faricimab and thus met the criteria to be included in the analysis. At the time of switch to faricimab the number of eyes having IRF, either alone or in combination with SRF, was 142 (30.0%) and the number of eyes with SRF, either alone or in combination with IRF, was 223 (47.2%). Following the switch to faricimab, for the 142 eyes with any IRF, 115 eyes (80.9%) had a reduction in IRF volume, and of the 223 eyes with SRF, 190 eyes (85.2%) had a reduction in SRF volume, and 64 of the 69 (92.8%) eyes with both IRF and SRF present had a reduction in both fluid subtypes. The interval distribution shifted from a mean of 5.78 ± 1.92 (SD) to 6.91 ± 2.26 (SD) weeks over the study period (p < 0.001). The mean BCVA improved from 63.91 ± 20.03 logMar letters to 69.25 ± 17.38 logMar letters (p < 0.001) after the switch.

conclusionsSwitching to faricimab in eyes with nAMD previously treated with other anti-VEGF agents was associated with anatomical and functional improvements in this selected cohort. Further prospective studies including the comparison with other anti-VEGF agents are warranted to more definitively evaluate the clinical benefits of faricimab in this setting.

Indexed as

Macula LuteaVisual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleRetrospective StudiesSubretinal FluidAngiogenesis InhibitorsAntibodies, BispecificfaricimabVascular Endothelial Growth Factor AAnti-VEGF therapyFaricimabIntraretinal fluidNeovascular age-related macular degenerationSubretinal fluid

Identifiers

PMID40820046
PMCPMC12675548

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.